论文部分内容阅读
目的 探讨化疗中Fas与肿瘤细胞耐药性的关系。方法 采用细胞生物学方法建立耐阿霉素的肝癌细胞HepG2株 ,并应用免疫组织化学方法观察该耐药细胞Fas表达水平的变化。 结果 未经阿霉素诱导的不耐药的HepG2细胞仅弱表达Fas ,并主要在细胞膜 ;耐阿霉素的HepG2细胞表达Fas增强 ,并以胞浆为主。同时细胞的死亡率亦发生变化 ,耐药株在 0 .1μg/ml阿霉素中的死亡率与非耐药株在无ADM中死亡率比较差异无显著性意义 (P >0 .0 5 ) ,但与非耐药株在 0 .1μg/mlADM中的死亡率比较差异则有显著性意义 (P <0 .0 5 )。 结论 Fas表达水平的变化可能是体内癌细胞耐药的机理之一。
Objective To investigate the relationship between Fas and drug resistance of tumor cells in chemotherapy. Methods The hepatoma cell line HepG2 with adriamycin resistance was established by cell biology method, and the expression of Fas was detected by immunohistochemistry. Results The Fas was weakly expressed in HepG2 cells without drug resistance induced by adriamycin, and mainly in the cell membrane; Fas enhanced in HepG2 cells resistant to doxorubicin and mainly in cytoplasm. At the same time, the mortality rate of the cells also changed. There was no significant difference in the death rate of drug-resistant strains between 0. 1 μg/ml adriamycin and non-resistant strains without ADM (P > 0.05). However, there was a significant difference in the mortality rate of non-resistant strains at 0.1 μg/ml ADM (P < 0.05). Conclusion The change of Fas expression may be one of the mechanisms of drug resistance in vivo.